Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
Retrieved on:
Wednesday, July 13, 2022
Tissue factor, The New England Journal of Medicine, Sodium, Thrombosis, IV, International Society, Multimedia, Factor XI, VII, Therapy, Collagen, Congress, Anthos, Factor, CVM, Patient, Endothelium, Fast track (FDA), Aspirin, Low-density lipoprotein receptor-related protein 8, Abciximab, Private Securities Litigation Reform Act, Platelet, Blood, Haemophilia C, Glycoprotein Ib, Lists of diseases, SC, Bleeding, Research, Poster, Ticagrelor, Cancer, FXI, Pharmaceutical industry
CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK.
Key Points:
- "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becoming increasingly clear.
- It demonstrated that abelacimab did not affect the level of antiplatelet inhibition achieved either by aspirin or ticagrelor confirming that abelacimab will not interfere with the benefits of these antiplatelet agents.
- Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
- Abelacimab targets the active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa.